Signature BioScience

Last updated
Signature BioScience
TypePrivate
IndustryBioPharmaceutical Discovery and Development
Founded1998
Defunct2003
Headquarters
San Francisco (initially Richmond)
,
USA
Key people
Mark McDade who was succeeded by Robert J. Zimmerman
Number of employees
approximately 100

Signature BioScience Inc. was the first biotechnology company based in San Francisco. It was formed in 1998 but closed in 2003 due to lack of funding. Before Signature was dissolved, it had just completed Phase II trials on Digitoxin, which the company was pursuing as an anti-cancer compound. However, the company's core competency was developing biotechnology tools that would be used to identify highly qualified pre-clinical leads.

Contents

History

Timeline

Signature BioScience (Signature) was founded by John Hefti, a theoretical physicist who received his doctorate from UC Berkeley and studied medicine at Stanford. [1] Signature’s main business model was to become a drug development company with preclinical leads available for licensing to pharmaceutical and biotech partners. Their main focus area was cancer, although they were in the process of developing some compounds in other therapeutic areas. Andrew Sandham later became president of the company and John Hefti became the CTO, with Mark McDade taking over as the CEO in late 2000. [2] [3] Towards the end of 2002, Robert J. Zimmerman succeeded Mark McDade, who left Signature to go to Protein Design Labs. Zimmerman became the President and a member of the Board of Directors, while maintaining his position as the COO; he had also formerly held the positions of EVP of Research & Development at Signature. [4] [5]

From January 1999 to February 2000, Dr. Amit Kumar was the founding President and Chief Executive Officer of Signature BioSciences Inc. Dr. Kumar did his graduate studies at Stanford University and the California Institute of Technology and received his Ph.D. from Caltech in chemistry in 1991. Later, he did is post-doctoral fellowship at Harvard University, where he developed patented techniques for building biochips and related devices. Furthermore, he had a great deal of experience working in the biotech industry and developing company’s platform technologies. [6] In November 2000, Mark McDade succeeded Dr. Kumar as the CEO. Mark McDade was the co-founder of Corixa in September 1994, had served on Corixa’s board since March 1999 and as the chief operating officer and director since 1994.

Signature became the first biotechnology company in San Francisco after acquiring 67,000 square feet (6,200 m2) of office and space in the city. They signed a 10-year lease in October 2001. [7] [8] Before all the employees and equipment moved into the new facility in May 2002, Signature increased its lease space to 100,000 square feet. [9] In April 2003, Signature decided to cease all operations when investors decided not to give the company a $10 million bridge loan. This loan was supposed to be used until the company completed a $30 million private equity from S.G. Capital Partners. [10]

Technology and products

Signature’s called its drug discovery platform, WaveScreen, could evaluate both cellular and molecular responses to compounds at the beginning of the drug discovery process. It used the technology itself and with partners, and commercialized instrumentation to implement it via a partnership with MDS Sciex. [11]

Signature also developed a cellular detection system based on its proprietary multipole coupling spectroscopy (MCS) technology which was based upon dielectric spectroscopy and used microwave and radio frequencies to scan proteins and cells. [12] [13] [14]

Financing

After leaving his work at Stanford and filing a patent, John Hefti raised $1 million in funding from Prospect Venture Partners (PVP) and Abingworth Management Inc. [15] In September 2000, Signature raised $17 million in a Series C private funding, which was led by Atlas Venture, and included CIBC Capital Partners and Coral Ventures as well as the company's original investors, ProspectVenture Partners and Abingworth Management. [16] In July 2001, Signature raised $43 million in a 4th round (Series D) of financing. The fund was led by SG Capital Partners, with the other existing investors participating in the round including PVP, Atlas Venture, Abinworth Management, CIBC Capital Partners, and Coral Ventures. The new investors in this round included SG Capital Partners, Vulcan Ventures Inc., MDS Capital Corp, China Development Industrial Bank, Tallwood Venture Capital, Lehman Brothers, Lotus Bioscience Ventures Ltd., and IRR. At this point, the company had raised a total of $64 million since its beginning in 1998. [17] Signature had assumed that their revenues, which would include the fees from pharmaceutical device companies, would reach $10 million at the end of 2001 and expected the numbers to skyrocket to $100 million by 2004. [18] However, the company dissolved after it failed to obtain a necessary bridge loan in 2003. [19]

Related Research Articles

Sheridan Gray Snyder OBE is an entrepreneur, venture capitalist, and philanthropist in the biotechnology industry. He is the founder and CEO of Biocatalyst, but also a "serial entrepreneur", a founder of Genzyme and many other companies. Snyder, who was the University of Virginia's best tennis player when he was studying for his BA in French and Romance Languages there in the 1960s, made "major contributions to the popularisation of tennis in the USA." He co-founded the National Junior Tennis League that reaches 250,000 inner-city young people and constructed a new tennis center at the University of Virginia.

Cristina Garmendia Spanish biologist and businesswoman (born 1962)

Dr. Cristina Garmendia y Mendizábal is a Spanish biologist and businesswoman. With no previous political career, she was appointed as Minister of Science and Innovation in April 2008 by the President of the Government of Spain, Jose Luis Rodriguez Zapatero.

The California Institute for Quantitative Biosciences (QB3) is a nonprofit research and technology commercialization institute affiliated with three campuses of the University of California in the San Francisco Bay Area: Berkeley, San Francisco, and Santa Cruz. QB3's domain is the quantitative biosciences: areas of biology in which advances are chiefly made by scientists applying techniques from physics, chemistry, engineering, and computer science.

Ivor Royston

Ivor Royston, M.D., is an oncologist, researcher, scientist, entrepreneur and venture capitalist, recognized for his efforts to develop treatments for multiple disease targets and to fund biotechnology companies with promising science, technology or medicines. He speaks regularly at healthcare conferences and symposia throughout the United States, Europe and Asia.

Francisco Partners American private equity firm

Francisco Partners is an American private equity firm focused exclusively on investments in technology and technology-enabled services businesses. Founded in August 1999 and based in San Francisco with offices in London and New York, Francisco Partners Management L.P. has raised approximately USD $24 billion in committed capital as of June 2020 when the firm raised nearly $10 billion for tech company investments. As of 2020, Francisco Partners had more than $25 billion in assets under management and invested in over 300 companies in the technology sector.

Alta Partners is a venture capital firm based in San Francisco which invests primarily in biotechnology and life science companies.

Sofinnova is the name shared by two venture capital firms, Sofinnova Partners and Sofinnova Ventures. The name Sofinnova is a contraction of the French, "Société de Financement de l’Innovation" or, Innovation Venture Capital Company. Both firms trace their roots back to Sofinnova SA, an investment institution founded in Paris in 1972. The two firms have raised ~$4B since inception and have generally shared a similar investment strategy of financing projects and ideas in the life sciences and technology sectors. The two firms distinguish themselves on the basis of their target geographies, stage of investment, and sectors. They have been independent entities since 1997.

Lux Capital American venture capital firm

Lux Capital is a venture capital firm based in New York City. It was founded in 2000, and focuses on investments in emerging technologies.

DocuSign American Technology Firm

DocuSign, Inc. is an American company headquartered in San Francisco, California, that allows organizations to manage electronic agreements. As part of the DocuSign Agreement Cloud, DocuSign offers eSignature, a way to sign electronically on different devices. DocuSign has over 1 million customers and hundreds of millions of users in more than 180 countries. Signatures processed by DocuSign are compliant with the US ESIGN Act and the European Union's eIDAS regulation, including EU Advanced and EU Qualified Signatures.

Atlas Venture is an early-stage venture capital firm that invests in life sciences startup companies in the U.S. Atlas is headquartered in Cambridge, Massachusetts, where the majority of its investments are located. Atlas rolled out its eleventh biotech fund totaling $350 million in June 2017, after closing its tenth fund in April 2015, with $280 million in commitments.

DNAnexus is an American company that provides a cloud-based data analysis and management platform for DNA sequence data. It is based in Mountain View, California, and was founded in 2009 by Stanford University professors Serafim Batzoglou and Arend Sidow and Stanford computer scientist Andreas Sundquist.

SOSV Venture capital firm

SOSV is a venture capital and investment management firm that provides seed, venture and growth stage funding to startup companies in the technology sector. The company's focus is on accelerating startups via their market specific seed accelerator programs located in Europe, Asia and the USA. The firm is made up of 8 general partners, 120+ full-time support staff and thousands of worldwide mentors. SOSV is headquartered in Princeton, New Jersey, with back office operations in Cork, Ireland, and flagship offices in San Francisco, Shenzhen, Shanghai, Taipei, New York, Cork, and London.

David Grainger is a partner at medicxi, a European life sciences-oriented venture capital firm and chief executive officer of Methuselah Health Ltd., a drug development company doing proteomics research in the longevity space.

BioMotiv is an accelerator company associated with The Harrington Project, a $340 million initiative centered at University Hospitals of Cleveland. Therapeutic opportunities are identified through relationships with The Harrington Discovery Institute, university and research institutions, disease foundations, and industry sources. Once opportunities are identified, BioMotiv oversees the development, funding, active management, and partnering of the therapeutic products.

OS Fund American venture capital fund

OS Fund is an American venture capital fund that invests in early-stage science and technology companies.

Henri Termeer

Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, alumni. Termeer is "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.

Aurora Biosciences

Aurora Biosciences was a biotechnology company founded in 1995 in San Diego to commercialize fluorescence assays based on Roger Y. Tsien's discoveries concerning green fluorescent protein and its uses in basic research - work for which Tsien eventually won the 2008 Nobel Prize in chemistry along with two other chemists.

Abingworth LLP is a London-based independent venture capital firm and registered investment advisory firm founded in 1973 by a pair of London stockbrokers, Peter Dicks and Anthony Montagu. Abingworth had initially sought to extend its investments into the biotechnology industry in the late 1980s, and has subsequently been investing in life science and healthcare services companies since at least 2001, and had expanded to include information technology firm investments by 2016.

Foresite Capital is an American venture capital and growth equity firm headquartered in San Francisco. As of March 2021, the company had raised four funds: Foresite Capital Fund I, II, III, IV and V.

Alexandria Real Estate Equities American real estate company

Alexandria Real Estate Equities, Inc. is an American real estate investment trust that invests in office buildings and laboratories leased to tenants in the life science and technology industries.

References

  1. ↑ Smith, L. "The Innovators: Meet the 65 Companies and Their Owners Who Have Conjured up the Latest Wave of Products, Services, and Technologies." (May 1, 2001.) 10/12/08 <http://www.cnnmoney.com.>
  2. ↑ Huggett, B. “Signature Raises $17 M Privately For PhenoDynamic Technology.” Bioworld Today Archives. September 7, 2000.
  3. ↑ “Signature Bio” 10/10/08 <http://www.archives.org.> Archived webpage: <http://signaturebio.com Archived 2003-12-01 at the Wayback Machine >
  4. ↑ “Signature BioScience CEO Goes to Protein Design Labs.” San Francisco Business Times. November 5, 2002.
  5. ↑ Article reference number: 112943. “Signature BioScience Announces Management Team Changes.” Biomedical NewsSearcher. November 5, 2002.
  6. ↑ “Acacia Research Names Dr. Amit Kumar as Vice President, Life Sciences; Medical Industry Entrepreneur Will Manage New San Francisco Area Office” Business Network (July 17, 2000) 10/11/08 <http://findarticles.com/p/articles/mi_m0EIN/is_2000_July_17/ai_63493789>
  7. ↑ Article reference number: 47955. "Signature Acquires Protein Design Labs’ Small Molecule Group." Biomedical NewsSearcher. January 29, 2002.
  8. ↑ Bishop, A. "Signature BioScience Signs 475 Brannan Lease." San Francisco Business Times. October 22, 2001.
  9. ↑ Doherty, B. "San Francisco Seeks Biotech Buy-In." San Francisco Business Times. March 1, 2002.
  10. ↑ Levine, D. "Signature Bio’s Burnout Singes City’s Ambition." Business Times. April 28, 2003.
  11. ↑ “Signature BioScience Signs With geneticXchange for Its discoveryHub Data Integration Solution.” Business Network. (June 4, 2002) 10/11/08 <http://findarticles.com/p/articles/mi_m0EIN/is_2002_June_4/ai_86679283>
  12. ↑ "MARK MCDADE - SIGNATURE BIOSCIENCE: TWST." 10/11/2008 <http://www.twst.com/notes/articles/nah364.html>.
  13. ↑ "Signature BioScience." Knowledge Express 2008.10/11/2008 <http://www.knowledgeexpress.com/recordview.asp?rid=4509&dbid=56&ListLoc=23&SourceFilter=%5B%5D>.
  14. ↑ Hefti, J., Pan, A., and Kumar, A., 1999. Sensitive detection method of dielectric dispersions in aqueous-based, surface-bound macromolecular structures using microwave spectroscopy. Applied Physics Letters 75(12):1802-1804.
  15. ↑ Huggett, B. “Signature Raises $17 M Privately For PhenoDynamic Technology.” Bioworld Today Archives. September 7, 2000.
  16. ↑ "Signature BioScience Raises $17 million." San Francisco Business Times. September 6, 2000
  17. ↑ Article reference number: 35208. "Signature Closes $43 million Series D Financing Round." Biomedical NewsSearcher. July 9, 2001.
  18. ↑ Smith, L. "The Innovators: Meet the 65 Companies and Their Owners Who Have Conjured up the Latest Wave of Products, Services, and Technologies." (May 1, 2001.) 10/10/08 <http://www.cnnmoney.com>
  19. ↑ Levine, Daniel (April 17, 2003). "Signature BioScience to shut down". San Francisco Business Times. Retrieved 2008-10-10.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.